TP53 and neoplasm: Lack of sensitivity to MDM2 inhibition could indicate the presence of a TP53 mutation, however whole-exome sequencing data revealed that all three TC PDX models contained wild type TP53. Ki-67 analysis showed no difference between control and RG7388 treated tumours.